Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.


NDAQ:ACRS - Post by User

Aclaris Therapeutics Inc
Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Nov 19, 2024 10:00am
11 Views
Post# 36319608

Overweight Recommendation Issued On ACRS By Piper Sandler

Overweight Recommendation Issued On ACRS By Piper Sandler
Breaking News: $ACRS Overweight Recommendation Issued On ACRS By Piper Sandler2024-11-19 03:30:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ACRS on November 18, 2024 07:54PM ET. ACRS was trading at $3.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 2...ACRS - Overweight Recommendation Issued On ACRS By Piper Sandler

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities